Paper41004518
Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out.
Wilbie D and 8 others. PLoS One, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out. Papers, record 41004518. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41004518
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-cancer compound screening identifies Aurora Kinase A inhibition as a means to favor CRISPR/Cas9 gene correction over knock-out.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| CRISPR-Cas Systems | Major topic |
| Aurora Kinase A | Major topic |
| Antineoplastic Agents | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Humans | |
| HEK293 Cells | |
| Gene Knockout Techniques | |
| Gene Editing | |
| Pyrimidines | |
| Drug Screening Assays, Antitumor | |
| Recombinational DNA Repair | |
| Cell Line, Tumor | |
| Azepines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 865.17.005 | Netherlands Organisation for Scientific Research (NWO) Talent program VICI | PubMed |
Source PubMed
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30944467 | Precise therapeutic gene correction by a simple nuclease-induced double-stranded break. | Nature | 2019 | https://conductscience.org/library/papers/30944467 | PubMed |
| 2 | 29538768 | Easy quantification of template-directed CRISPR/Cas9 editing. | Nucleic Acids Res | 2018 | https://conductscience.org/library/papers/29538768 | PubMed |
| 3 | 3663476 | A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. | Br J Cancer | 1987 | https://conductscience.org/library/papers/3663476 | PubMed |
| 4 | 29804829 | Kinetics and Fidelity of the Repair of Cas9-Induced Double-Strand DNA Breaks. | Mol Cell | 2018 | https://conductscience.org/library/papers/29804829 | PubMed |
| 5 | 26437586 | Repair Pathway Choices and Consequences at the Double-Strand Break. | Trends Cell Biol | 2016 | https://conductscience.org/library/papers/26437586 | PubMed |
| 6 | 31178391 | Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates. | Mol Ther | 2019 | https://conductscience.org/library/papers/31178391 | PubMed |
| 7 | 31099553 | Delivery Aspects of CRISPR/Cas for in Vivo Genome Editing. | Acc Chem Res | 2019 | https://conductscience.org/library/papers/31099553 | PubMed |
| 8 | 26612622 | Exosomes from hypoxic endothelial cells have increased collagen crosslinking activity through up-regulation of lysyl oxidase-like 2. | J Cell Mol Med | 2016 | https://conductscience.org/library/papers/26612622 | PubMed |
| 9 | 30189348 | The influence of eukaryotic chromatin state on CRISPR-Cas9 editing efficiencies. | Curr Opin Biotechnol | 2019 | https://conductscience.org/library/papers/30189348 | PubMed |
| 10 | 20382844 | A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. | Blood | 2010 | https://conductscience.org/library/papers/20382844 | PubMed |
| 11 | 28177771 | Precision genome editing in the CRISPR era. | Biochem Cell Biol | 2017 | https://conductscience.org/library/papers/28177771 | PubMed |
| 12 | 40242216 | CRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders. | Front Genome Ed | 2025 | https://conductscience.org/library/papers/40242216 | PubMed |
| 13 | 28939824 | In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting. | Nat Commun | 2017 | https://conductscience.org/library/papers/28939824 | PubMed |
| 14 | 29490262 | A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing. | Cell Rep | 2018 | https://conductscience.org/library/papers/29490262 | PubMed |
| 15 | 38191764 | Extracellular vesicle-mediated delivery of CRISPR/Cas9 ribonucleoprotein complex targeting proprotein convertase subtilisin-kexin type 9 (Pcsk9) in primary mouse hepatocytes. | J Extracell Vesicles | 2024 | https://conductscience.org/library/papers/38191764 | PubMed |
| 16 | 26458548 | Highly efficient CRISPR/HDR-mediated knock-in for mouse embryonic stem cells and zygotes. | Biotechniques | 2015 | https://conductscience.org/library/papers/26458548 | PubMed |
| 17 | 32207531 | Gene editing and CRISPR in the clinic: current and future perspectives. | Biosci Rep | 2020 | https://conductscience.org/library/papers/32207531 | PubMed |
| 18 | 40373211 | Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40373211 | PubMed |
| 19 | 30687381 | Methodologies for Improving HDR Efficiency. | Front Genet | 2018 | https://conductscience.org/library/papers/30687381 | PubMed |
| 20 | 28512351 | Non-homologous DNA end joining and alternative pathways to double-strand break repair. | Nat Rev Mol Cell Biol | 2017 | https://conductscience.org/library/papers/28512351 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42300182 | Azide-functionalized SpCas9 enables generation of site-selective and bioactive Cas9-siRNA conjugates. | Chem Commun (Camb) | 2026 | https://conductscience.org/library/papers/42300182 | PubMed |
| 40674218 | Protocol to rapidly screen CRISPR-Cas9 gene editing outcomes in a cell population by mutating eGFP to a blue or non-fluorescent phenotype. | STAR Protoc | 2025 | https://conductscience.org/library/papers/40674218 | PubMed |
| 40533769 | Aurora kinases signaling in cancer: from molecular perception to targeted therapies. | Mol Cancer | 2025 | https://conductscience.org/library/papers/40533769 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AURKA | 6790 | PubTator's text mining | https://conductscience.org/library/genes/6790 | NCBI Gene |
| LIG4 | 3981 | PubTator's text mining | https://conductscience.org/library/genes/3981 | NCBI Gene |
| PARP1 | 142 | PubTator's text mining | https://conductscience.org/library/genes/142 | NCBI Gene |
| PARP2 | 10038 | PubTator's text mining | https://conductscience.org/library/genes/10038 | NCBI Gene |
| RAD51 | 5888 | PubTator's text mining | https://conductscience.org/library/genes/5888 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41004518
GET https://conductscience.org/api/papers/v1/41004518/references?page=2